
BioVentures Partners with Auxigen on NIH-Funded Entrepreneurship Training Platform
BioVentures is collaborating with Arkansas-based Auxigen to develop and test Auxigen: BIO, an adaptive, artificial intelligence-enhanced commercialization training platform for University of Arkansas for Medical Sciences (UAMS) biomedical researchers. Jakob Michaelis, CEO of Auxigen said, “Auxigen was founded on the belief that with the right insights, more businesses can be successful. Researchers are trained to do excellent science. Getting discoveries to market feels murky, and the data proves it. Auxigen:BIO aims to provide more clarity through understanding where the researcher is at and providing personalized next steps that matter for their technology. I am excited to partner with the BioVentures team, their collective expertise, and researcher relationships to see the measurable impact of this approach.” Auxigen leads the project through a $308,890 Phase I Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences, part of the National Institutes of Health. BioVentures leads the UAMS subaward for this project, contributing biomedical commercialization expertise and connections to the UAMS research community. The federal SBIR program funds small businesses to develop innovative technologies with commercial potential, with participation across the U.S. Department of Health and Human Services from 24 NIH institutes and centers, as well as the CDC, FDA, Administration for Community Living and Advanced Research Projects Agency for Health. The collaboration addresses a common challenge: scientists often receive extensive research training but limited preparation for bringing innovations to market. Auxigen:BIO will tailor learning pathways to each venture’s technology and development stage, helping researchers focus on relevant guidance. For example, therapeutic and diagnostic developers could receive different regulatory training. UAMS faculty, investigators, postdoctoral fellows and graduate students will participate in initial testing. Participants will work toward practical outputs, including project pitches to support SBIR preparation, business models, early-stage regulatory plans and customized commercialization roadmaps. Phase I of this SBIR project will focus on developing biomedical training modules, improving AI tools for venture-specific guidance and assessing participant progress. Evaluation will examine engagement, commercialization knowledge and activities such as team formation and pursuit of follow-on funding. For Phase II, the goal will be to refine the platform and expand access statewide and nationally. The Auxigen:BIO partnership combines Auxigen’s entrepreneurship technology with BioVentures’ commercialization experience to help researchers advance promising discoveries toward healthcare applications, supporting BioVentures’ mission to enhance human healthcare and stimulate economic development in Arkansas.